ReviewCancers2022
Pancreatic Cancer: Challenges and Opportunities in Locoregional Therapies.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of apatinib combined with radiotherapy in the treatment of advanced pancreatic cancer: a meta-analysis.World journal of surgical oncology · 2023Pooled it
- LncRNA MIR22HG and miR-10a-5p: Pioneering serum biomarkers for pancreatic cancer diagnosis and progression assessment.Non-coding RNA research · 2026Article
- Quantum-Augmented Federated AI for Adaptive Pharmacogenomic Precision Oncology: A Perspective.ACS pharmacology & translational science · 2026Review
- Twist1 overexpression models an aggressive subtype of pancreatic ductal adenocarcinoma in vivo.Lab animal · 2026Article
- Article
- METTL3-driven mJournal of translational medicine · 2026Article
- Brain metastasis from KRAS wild-type pancreatic cancer and organoid correlates: a case report.Journal of gastrointestinal oncology · 2026Article
- The RASSF1C-HIF-1α axis drives macrophage lipid metabolism to promote pancreatic cancer.Cell death & disease · 2026Article
- Radiosensitization effects of BaTiO₃ and gold nanoparticles in proton therapy of pancreatic tumors: A Monte Carlo study.Iranian journal of basic medical sciences · 2026Article
- Stent Patency and Survival after PTBD and Biliary Stenting for Pancreatic Cancer: A 5-Year Retrospective Cohort Study.Archives of Iranian medicine · 2025Article
- Calcium hydroxide nanoparticles induce apoptotic cell death in human pancreatic cancer cells through over ROS-driven genomic instability and mitochondrial dysfunction.Scientific reports · 2025Article
- Design and optimization of PLGA-based gemcitabine nanocapsule for enhanced pancreatic cancer efficacy.Investigational new drugs · 2025Article
- Article
- Review
- Bioactive potency of extracts fromBiomedical reports · 2025Article
- Endoscopic-Ultrasound-Guided Radiofrequency Ablation for Pancreatic Tumors.Journal of clinical medicine · 2025Review
- An overview of the feasibility of nanomedicine in pancreatic cancer theranostics.Exploration of targeted anti-tumor therapy · 2025Review
- Exploring radiation resistance-related genes in pancreatic cancer and their impact on patient prognosis and treatment.Frontiers in immunology · 2025Article
- Different Cytotoxic Effects of Cisplatin on Pancreatic Ductal Adenocarcinoma Cell Lines.International journal of molecular sciences · 2024Article
- Metal-organic frameworks as nanoplatforms for combination therapy in cancer treatment.Medical oncology (Northwood, London, England) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer (PC) remains the seventh leading cause of cancer-related deaths worldwide and the third in the United States, making it one of the most lethal solid malignancies. Unfortunately, the symptoms of this disease are not very apparent despite an increasing incidence rate. Therefore, at the time of diagnosis, 45% of patients have already developed metastatic tumours. Due to the aggressive nature of the pancreatic tumours, local interventions are required in addition to first-line treatments. Locoregional interventions affect a specific area of the pancreas to minimize local tumour recurrence and reduce the side effects on surrounding healthy tissues. However, compared to the number of new studies on systemic therapy, very little research has been conducted on localised interventions for PC. To address this unbalanced focus and to shed light on the tremendous potentials of locoregional therapies, this work will provide a detailed discussion of various localised treatment strategies. Most importantly, to the best of our knowledge, the aspect of localised drug delivery systems used in PC was unprecedentedly discussed in this work. This review is meant for researchers and clinicians considering utilizing local therapy for the effective treatment of PC, providing a thorough guide on recent advancements in research and clinical trials toward locoregional interventions, together with the authors' insight into their potential improvements.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.